cfDNA Analysis in ALK-positive NSCLC Patients and Potential Clinical Utility
Jean-francois Martini,
Sr. Director, Translational Oncology, Immuno-Oncology, Early Development,
Pfizer
Lorlatinib exhibited antitumor activity across a variety of ALK kinase
domain resistance mutations, including the difficult-to-treat ALK G1202R
mutation. Responses to lorlatinib were also seen in patients resistant
to prior ALK TKIs and without detectable ALK resistance mutations in
plasma.
|
|
